CODING AND BILLING GUIDE FOR THE USE OF SOLIRIS[®] (eculizumab)

In Adult Patients With Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG)¹

INDICATION

Soliris is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early.

- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
- Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of developing a meningococcal infection. (See *Serious Meningococcal Infections* for additional guidance on the management of the risk of meningococcal infection).
- Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at <u>www.solirisrems.com</u>.



Purpose of This Guide and Disclaimer

Alexion Pharmaceuticals, Inc. has developed the SOLIRIS[®] (eculizumab) Coding and Billing Guide to provide objective and publicly available coding and billing information.

This document is provided for informational purposes only and is not legal advice or official guidance from payers. It is not intended to increase or maximize reimbursement by any payer. Alexion does not warrant, promise, guarantee, or make any statement that the use of this information will result in coverage or payment for SOLIRIS, or that any payment received will cover providers' costs. Alexion is not responsible for any action providers take in billing for, or appealing, SOLIRIS claims.

Hospitals and physicians are responsible for compliance with Medicare and other payer rules and requirements and for the information submitted with all claims and appeals. Before any claims or appeals are submitted, hospitals and physicians should review official payer instructions and requirements, should confirm the accuracy of their coding or billing practices with these payers, and should use independent judgment when selecting codes that most appropriately describe the services or supplies provided to a patient.

Please visit <u>www.soliris.net</u> for additional information or call 1-888-765-4747 to speak with the Alexion OneSource[™] Team.

Coding for SOLIRIS® (eculizumab) in Anti-AChR Antibody-Positive gMG

Diagnosis Coding

The following International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes may be appropriate to describe patients diagnosed with gMG who are anti-AChR antibody positive:

ICD-10-CM Diagnosis Code ²	Code Descriptor
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

Drug Coding

The following Healthcare Common Procedure Coding System (HCPCS) billing code can be reported on medical claim forms to payers:

HCPCS Code ³	Code Descriptor
J1300	Injection, eculizumab, 10 mg

Some payers may also require the use of HCPCS modifier -RE to indicate SOLIRIS was administered in full compliance with the REMS program.

Some payers, including Medicaid, require drugs like SOLIRIS to be billed on medical claims with the product's National Drug Code (NDC) in addition to the HCPCS code. Payers typically require healthcare professionals to use the Health Insurance Portability and Accountability Act (HIPAA)-compliant, 11-digit NDC format⁴:

11-Digit NDC ^{1,4}	Code Descriptor	Strength
25682-0001-01	SOLIRIS single-use vial	300 mg/30 mL

Please note that payers have different guidance for placement of the NDC on medical claims. Typically, the 11-digit NDC is reported without any dashes or other punctuation.⁴

Some payers may also require a unit of measure (UoM) qualifier. For SOLIRIS, the unit of measure qualifier is mL (milliliter).

Check payer requirements for reporting the NDC and UoM on claims.

Drug Administration Services

Payers may offer separate coverage and reimbursement for drug administration services. The following are possible ICD, 10th Revision, Procedure Coding System (ICD-10-PCS) procedure codes to report the administration of SOLIRIS in inpatient settings:

ICD-10-PCS⁵	Code Descriptor
3E033GR	Introduction of other therapeutic monoclonal antibody into peripheral vein, percutaneous approach
3E043GR	Introduction of other therapeutic monoclonal antibody into central vein, percutaneous approach

The following Current Procedural Terminology (CPT[®]) codes may be appropriate to report administration of SOLIRIS in physician offices and hospital outpatient facilities. Individual payer policies should be reviewed for reporting requirements.

CPT Code ⁶	Code Descriptor
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to one hour
96413	Chemotherapy administration, intravenous infusion technique, up to one hour, single or initial substance/drug

Coding for Meningococcal Vaccination

Diagnosis Coding

For an encounter strictly for the vaccination, the diagnosis code for prophylactic vaccination is assigned along with the diagnosis code for gMG and any other conditions the patient may have.

ICD-10-CM Diagnosis Code ²	Code Descriptor
Z23	Encounter for immunization

Vaccine Coding

Coverage of meningococcal vaccines may vary by payer. Prescribers should consult respective payer billing guidelines.

CPT Code ⁶	Code Descriptor
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2-dose schedule, for intramuscular use
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use
90733	Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use
90734	Meningococcal conjugate vaccine, serogroups A, C, Y, and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use

Vaccine Administration Coding


The following CPT codes may be appropriate to report administration of meningococcal vaccines in outpatient settings.

CPT Code ⁶	Code Descriptor
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
+ 90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Claim Forms

Sample CMS-1500 (or the electronic equivalent 837P): Physician Office

For an example of a completed CMS-1500 form, go to page $\underline{6}$.



- 96365 for drug administration

Sample CMS-1500 (or the electronic equivalent 837P): Physician Office Example claim form for a SOLIRIS[®] (eculizumab) IV infusion:


To achieve a SOLIRIS maintenance dose of 1200 mg for a patient 18 years of age and older, the following vials were used:

• 4 single-use 300 mg/30 mL vials (NDC 25682-0001-01)

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a.				17a.	17a.			18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES					
17b. NPI						FROM TO							
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)						20. OUTSIDE LAB? \$ CHARGES							
							YES NO						
	21. DIAGNOSIS OR NATU	IRE OF ILLNESS OR INJ	IURY Relate	A-L to service line below (24	^{1E)} ICD Ind.		22. RESU	BMISSION		ORIGINAL F	EF NO		
	A. G70.00	в. Ц		с	- D. I			-					
	Е	F. L		а. — ні			23. PRIO	R AUTHORIZ	ATION NUI	MBER			
	L	J		К.	_ L. L								
	24. A. DATE(S) OF S From	ERVICE B To PLACE		D. PROCEDURES, SERVIC		E. DIAGNOSIS		F.	G. DAYS	H. I. EPSDT ID	J. RENDEF	Z	
	MM DD YY M			(Explain Unusual Circu CPT/HCPCS	MODIFIER	POINTER	\$ CH	ARGES	OR UNITS	Family ID. Plan QUAL.	PROVIDER		
1	N425682000101 ML	120										M	
1.	MM DD YY	11		J1300		А	2	XXX XX	120	NPI			
2										•			
4	MM DD YY	11		96365		Α	2	XXX XX	1	NPI		<u> </u>	
3												SUPPLI	
1										NPI		§	
4												OR S	
'								ltem 2	24E D	iagnosi	is 🔤		
F		1 1 1			1 I I			Point	er: En	ter the	letter	PHYSICIAN	
1.5.3							corresponding to the						
lt	em 24A (Shadeo	: Area): The "N	N4"	Item 24D Procedures/Services/				diagnosis and in Itam 21					
qı	ualifier is require	ed before the		Supplies: Enter the appropriate									
	DC; do not inclu		Ľ	HCPCS/CPT codes and modifiers; e			eg.	TAL COMPACT CONTRACT FOR THE CONTRACT FOR N JCC Use					
	,						0,						
So	ome payers may	also require a		 J1300 Injection, eculizumab, 									
U	nit of Measure (UoM) for each	า	10 mg									
NDC; eg,								ltem 3	24G D	avsor	Units: Ente	r the	
					travenous inf	,	Item 24G Days or Units: Enter the appropriate number of units for J1300						
	 N425682000101 ML120 			for thera	py, prophylax	is, or			•				
Note: Check payer requirements and				diagnosis (specify substance o			r per 10 mg. For example, enter 120						
format for reporting the NDC and				drug); initial, up to 1 hour				billing units for 1200 mg.					
						541							
υ	oM.												

Sample CMS-1450 (UB-04) (or the electronic equivalent 837I): Hospital Outpatient Clinic or Facility

For an example of a completed CMS-1450 form, go to page $\underline{8}$.



Sample CMS-1450 (UB-04) (or the electronic equivalent 837I): Hospital Outpatient Clinic or Facility

Example claim form for a SOLIRIS® (eculizumab) IV infusion:

To achieve a SOLIRIS maintenance dose of 1200 mg for a patient 18 years of age and older, the following vials were used:

• 4 single-use 300 mg/30 mL vials (NDC 25682-0001-01)

	42 REV. CD.	43 DESCRIPTION	4		44 HCPCS / RATE / HIPPS CO	DE	45 SERV. DATE	46 SERV	. UNITS	47 TOTAL CH	ARGES	48 NON-COVERED CHARGES
1	0636	N4256820	00101 ML120 SOLIRIS		J1300		MM DD YY		120		XXX XX	
2	0510	IV infusion,	initial, up to 1 hour		96365		MM DD YY		1	-	XXX XX	
3												
4											÷	
De Th be da So M -	escript ie "N4' fore th shes. me pa easure N42. ote: Dou	" qualifier ne NDC; d yers may e (UoM) fo 5682000 uble check	Revenue is required do not include require a Unit of or each NDC; eg, 101 ML120 payer requirements rting the UoM.	HIPPS HCPC - Dr (ed	Locator 44 HCF Code: Enter th S/CPT codes ar rug: J1300 for S culizumab) per 3 365 for drug ac	e approj id modifi OLIRIS 10 mg	oriate ers; eg,		Enter of unit	the appr s for J1 ample, e	ropriate 300 per	
19 20 21 22 23		PAGE	OF		CREATIC	N DATE		ΤΟΤΑ	ALS			
İ	50 PAYER N	IAME		51 HEALTH PLAN	ID 52 I		PRIOR PAYMENTS	55 E	EST. AMOUNT	DUE	56 NPI	
A										:	57	
в											OTHER	
с											PRV ID	
A B C A B	58 INSUREE	D'S NAME	Form Locator 67 P appropriate diagno – ICD-10-CM: G – ICD-10-CM G Note: Other diagno	osis code; e 70.00 for N 70.01 for N	eg, Myasthenia grav Iyasthenia grav	/is witho	ut (acute) e	exace	rbatior		Enter the	P NO.
c	66					_				(2)		68
ĺ								6		P		
ł	69 ADMIT		70 PATIENT REASON DX	b	C A	S	12 ECI	a		b		73
		PRINCIPAL PROCI DE		ROCEDURE DATE	b. OTHER PROC		be l	ATTENDI	NG NPI	~		QUAL

SELECT IMPORTANT SAFETY INFORMATION (cont.)

Contraindications

- Patients with unresolved serious Neisseria meningitidis infection
- Patients who are not currently vaccinated against *Neisseria meningitidis*, unless the risks of delaying Soliris treatment outweigh the risks of developing a meningococcal infection

Warnings and Precautions

Serious Meningococcal Infections

Risk and Prevention

The use of Soliris increases a patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis).

Vaccinate or revaccinate for meningococcal disease according to the most current ACIP recommendations for patients with complement deficiencies. Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of Soliris. If Soliris must be initiated immediately in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide 2 weeks of antibacterial drug prophylaxis. Discontinue Soliris in patients who are undergoing treatment for serious meningococcal infections.

REMS

Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s).

Other Infections

Serious infections with *Neisseria* species (other than *N. meningitidis*), including disseminated gonococcal infections, have been reported.

Patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, *Aspergillus* infections have occurred in immunocompromised and neutropenic patients. Use caution when administering Soliris to patients with any systemic infection.

Infusion-Related Reactions

Administration of Soliris may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. Interrupt Soliris infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

Adverse Reactions

The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (\geq 10%) is: musculoskeletal pain.





Alexion Access Navigator is a dedicated resource website for US Healthcare Professionals and their offices that contains downloadable access and reimbursement materials for SOLIRIS[®] (eculizumab).

Online: https://alexionaccessnavigator.com

OneSource™ Offers Patient Support

Contact OneSource™:

Phone: 1-888-765-4747 Online: https://alexiononesource.com/

References

- 1. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
- 2. Centers for Medicare & Medicaid Services. 2023 ICD-10-CM. Updated June 7, 2022. Accessed October 13, 2022. https://www.cms.gov/files/zip/2023-code-tables-tabular-and-index.zip
- 3. Centers for Medicare & Medicaid Services. January 2022 alpha numeric HCPCS file. Updated January 26, 2022. Accessed October 13, 2022. <u>https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update</u>
- Food and Drug Administration. Future format of the National Drug Code; public hearing; request for comments. Fed Regist. 2018;83(152):38666-38668. Accessed October 13, 2022. <u>https://www.federalregister.gov/</u> <u>documents/2018/08/07/2018-16807/future-format-of-the-national-drug-code-public-hearing-request-for-comments</u>
- 5. Centers for Medicare & Medicaid Services. 2023 ICD-10-PCS code tables and index. Updated May 26, 2022. Accessed October 13, 2022. <u>https://www.cms.gov/medicare/icd-10/2023-icd-10-pcs</u>
- 6. 2022 CPT Professional. American Medical Association; 2021. CPT © 2021 American Medical Association. All rights reserved. CPT[®] is a registered trademark of the American Medical Association.

Please see additional Important Safety Information on pages <u>1</u> and <u>9</u> and the full <u>Prescribing Information</u> for SOLIRIS[®] (eculizumab), including Boxed WARNING regarding serious meningococcal infections.

SOLIRIS, ALEXION, and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. OneSource is a trademark of Alexion Pharmaceuticals, Inc. © 2022, Alexion Pharmaceuticals, Inc. All rights reserved.

